Conflict of interest: Nothing to declare.
Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia†
Article first published online: 19 SEP 2012
Copyright © 2012 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 3, pages 420–427, March 2013
How to Cite
Volejnikova, J., Mejstrikova, E., Dörge, P., Meissner, B., Zimmermannova, O., Svojgr, K., Stanulla, M., Cario, G., Schrappe, M., Stary, J., Hrusak, O., Trka, J. and Fronkova, E. (2013), Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia. Pediatr. Blood Cancer, 60: 420–427. doi: 10.1002/pbc.24299
- Issue published online: 15 JAN 2013
- Article first published online: 19 SEP 2012
- Manuscript Accepted: 6 AUG 2012
- Manuscript Received: 7 MAR 2012
- Czech Ministry of Health. Grant Number: NT 12397-4
- German Federal Ministry of Education and Research (BMBF; NGFN project number 01GS0442)
- Deutsche Krebshilfe
- Madeleine Schickedanz Kinderkrebs-Stiftung
- Charles University Prague. Grant Number: GAUK 363011
- GAČR Centre of Excellence. Grant Number: P302/12/G101
Additional Supporting Information may be found in the online version of this article.
|pbc_24299_sm_SuppFig1.tif||32621K||Supplementary Figure 1.|
|pbc_24299_sm_SuppFig2.tif||32621K||Supplementary Figure 2.|
|pbc_24299_sm_SuppFig3.tif||32621K||Supplementary Figure 3.|
|pbc_24299_sm_SuppFig4.tif||1485K||Supplementary Figure 4.|
|pbc_24299_sm_SuppFig5.tif||1380K||Supplementary Figure 5.|
|pbc_24299_sm_SuppFig6.tif||1459K||Supplementary Figure 6.|
|pbc_24299_sm_SuppTabI.docx||25K||Supplemental Table I. Representativity of the study cohort with respect to i) cohort of patients with ALL treated following the ALL IC-BFM 2002 protocol in the study period without an available IKZF1 status, ii) validation cohort.|
|pbc_24299_sm_SuppTabII.docx||14K||Supplemental Table II. Relative representation of individual IKZF1 isoforms in patients with ALL and in healthy controls.|
|pbc_24299_sm_SuppTabIII.docx||21K||Supplemental Table III. Characteristics of patients with IKZF1 alterations (gene deletion or Ik6 overexpression) treated following the ALL IC-BFM 2002 protocol.|
|pbc_24299_sm_SuppTabIV.docx||12K||Supplemental Table IV.Sequences of primers and probes used in qPCR for IKZF1 isoforms.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.